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AfterdepolarizationsTreating arrhythmias is a challenge for clinicians because pharmacological therapies are often ineffective or
have severe side effects. Patients with heart failure frequently present with supreventricular and ventricular
arrhythmias. New antiarrhythmic therapies are needed that modulate the speciﬁc pathomechanisms under-
lying the development of cardiac arrhythmias and may have a better safety-proﬁle. The Ca-calmodulin
dependent kinase II (CaMKII) seems to be involved in the development of heart failure and arrhythmias
and may therefore be a promising target for the development of antiarrhythmic therapies. The current review
aims at discussing some novel as well as known cytosolic and sarcolemmal mechanisms involved in
CaMKII-dependent arrhythmias without being able to cover all aspects known in the ﬁeld. This article is
part of a Special Issue entitled "Calcium Signaling in Heart".
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The treatment of cardiac arrhythmias remains a major challenge for
clinicians due to their high prevalence and the limitations of currently
available pharmacological therapies. Arrhythmias can be subdivided
into supra-ventricular and ventricular arrhythmias, both of which
potentially have severe consequences. Atrial ﬁbrillation (AF), forologie/Herzzentrum, Deutsches
ersität Göttingen, Robert-Koch-
; fax: +49 551 39 14131.
Maier).
NC-ND license.example, is the most common sustained arrhythmia and confers a
5-fold risk of stroke [1]. As pharmacological therapies often are inef-
fective in preventing AF recurrence or even exert severe side effects
(e.g. amiodarone or ﬂecainide), invasive procedures like pulmonary
vein isolations are frequently needed, bringing about further risks
for patients. Additionally, the bulk of patients with AF has to be treat-
ed with anticoagulants and is thus subjected to a higher risk of hemor-
rhage. Better medical control of this supra-ventricular arrhythmia
would be of great beneﬁt. Furthermore, heart failure is associated with
a strongly increased risk of sudden cardiac death. In fact, it is well
known that approximately 40% of heart failure patients die due tomalig-
nant ventricular arrhythmias [2]. The over-all prevalence of heart failure
is estimated to be around 2% [3] and will further increase due to demo-
graphic changes. There are estimated survival rates of only 50% for
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tion between heart failure and arrhythmias confronts clinicians with a
demanding task because many inotropic agents used in the setting of
decompensated acute heart failurewere shown to increase the likelihood
of suddendeath [7] and current antiarrhythmic drugs acting on sarcolem-
mal ion channels often confer proarrhythmic side effects on functionally
impaired myocardium [8]. Thus, new antiarrhythmic therapies are
needed that can directly modulate the speciﬁc pathomechanisms under-
lying the development of cardiac arrhythmias in the respective clinical
context (e.g. atrial ﬁbrillation/atrial remodeling or heart failure) and
hence harbor a more effective and safer action-proﬁle. Huge efforts
have beenmade in the last decade to further elucidate this issue. Increas-
ing evidence indicates that the Ca-calmodulin dependent kinase II
(CaMKII) could be a promising new target for such future antiarrhythmic
therapies [9].1.1. The physiological role of CaMKII in Ca cycling
CaMKII, a serine/threonine protein kinase, is a key regulator of Ca
cycling in cardiomyocytes. It has been known for a long time that
CaMKII modulates Ca inﬂux, SR Ca release and SR Ca reuptake during
excitation–contraction coupling. These effects are mainly exerted by
phosphorylation of several key Ca handling proteins. CaMKII was
shown to functionallymodulate ryanodine receptor type 2 (RyR2) func-
tion in the sarcoplasmatic reticulum (SR) [10]. CaMKII-dependent RyR2
phosphorylation (at Ser2815) results in a pronounced RyR2-activation
[11]. Another target of CaMKII is phospholamban (PLN, at Thr17). PLN
is a physiological inhibitor of the SR Ca ATPase 2a (SERCA2a) and one
of the major mediators of the cardiac contractility response upon
β-adrenergic stimulation [12]. The inhibition of SERCA2a by PLN is de-
pendent on the phosphorylation status of PLN and is most pronounced
when PLN is dephosphorylated. Phosphorylation of PLN by CaMKII acti-
vates SERCA2a leading to enhanced SR Ca-reuptake. Furthermore,
CaMKII has been shown to regulate sarcolemmal L-type Ca-currents
[13] as well as Na-currents [14].
Physiologic regulatory roles of CaMKII have been demonstrated as
to the adaptation of Ca cycling parameters to cellular demands in the
context of the force-frequency-relationship [15] and the ﬁght or ﬂight
response [16]. Also, CaMKII has been shown to be centrally involved
in cardiac recovery from acidosis [17,18].
There is however convincing evidence that chronic overactivation of
CaMKII is associated with deterioration of myocardial function and
is also causally linked to cardiac arrhythmias in different cardiac1 
m
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Fig. 1. Arrhythmogenic effects of CaMKII in vivo: ECG recordings from CaMKIIδc-TG mice sh
inhibited by inhibiting CaMKII with KN-93.
Modiﬁed from Sag et al., Circ Heart Fail, 2009.pathologies. In fact, transgenic overexpression of the CaMKII iso-
form δc induces severe hypertrophy and heart failure [19] and
CaMKIIδc overexpressing mice are more prone to arrhythmias [20]
(see Fig. 1). The fact that CaMKII was shown to be activated by auto-
phosphorylation at Thr287 [21] as well as oxidation at Met281/282
[22,23] enables a disproportionate CaMKII activation to set in during
conditions of diastolic Ca overload and shortage of energy supply.
Interestingly, CaMKII was found to be upregulated in heart failure
[24] as well as in atrial ﬁbrillation [25,26]. Up to date, several ion
channels have been identiﬁed as CaMKII targets and may possibly
contribute to the initiation of arrhythmias by triggering early and
delayed afterdepolarizations.1.2. The ryanodine receptor type 2
Several groups have demonstrated the pathologically relevant
impact of CaMKII on RyR2 function in animal models as well as in
human disease [19,20,27–30]. Hyperphosphorylation of RyR2 by
CaMKII at Ser2815 leads to an impaired diastolic RyR2 closure, resulting
in an increased frequency of short and tightly localized SR Ca release
events during diastole (Ca sparks) [19,27] (see Fig. 2). One Ca spark is
generated from a limited number of clustered RyR2s that form a func-
tional SR Ca release unit. The spontaneous opening of one receptor can
consecutively trigger the activation of neighboring RyR2s of the same
Ca release unit in the dyadic cleft via Ca induced Ca release (CICR) [31].
This mechanism on the one hand can contribute to a depletion of SR Ca
storage,which leads to impaired contractility [19,27] andalso constitutes
an arrhythmic trigger on the other hand. Ca ions, once released, are part-
ly removed from the cytosol via the Na/Ca exchanger (NCX) that elimi-
nates one Ca ion in exchange for three Na ions and thus evokes a
transient inward current (ITi). In this manner, the elimination of leaking
Ca from the SR can lead to a depolarization of the cell membrane that
possibly reaches the threshold potential and triggers an action potential
causing delayed afterdepolarizations [32]. It could be shown in atrial
cardiomyocytes from guinea pigs that cellular Ca overload induces de-
layed afterdepolarizations and sustained triggered activity [33] in an
NCX-dependent manner, thus conﬁrming the hypothesis of a Ca in-
duced transient inward current via NCX. This mechanism is aggravated
in heart failure and atrial ﬁbrillation by the fact that NCX is higher
expressed in these pathologies [24,34,35]. Furthermore, transgenic
mice overexpressing CaMKII showed an increased diastolic SR Ca leak
triggering a larger number of delayed afterdepolarizations through ITi
and spontaneous action potentials compared to wild type mice [20].CaMKII-Inhibition 
KN-93  
ythmias 
Control 
KN-92  
owing arrhythmias after isoproterenol stress (2 mg/kg body weight), which could be
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Fig. 2. CaMKII-dependent arrhythmogenic mechanisms: SR Ca leak: SR Ca leak in atrial myocytes from AF patients, as measured by Ca sparks (red arrows) showing enhanced SR Ca
leak under control conditions (KN-92) and reduction of SR Ca leak upon CaMKII inhibition (KN-93).
Modiﬁed from Neef et al., Circ Res, 2010.
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these mice in vitro as well as in vivo. Additionally, knock-in mice with
a point mutation mimicking constitutive RyR2 phosphorylation at
the CaMKII dependent site Ser2814 (equals Ser2815 in human)
showed higher diastolic spark frequencies and an increased suscep-
tibility to pacing-induced AF [26]. Also, mice known to have cate-
cholaminergic polymorphic ventricular arrhythmias due to the
RyR2 point mutation R4496C show strongly increased mortality
when crossbred with CaMKII transgenic mice [36]. The observed
clinical signs of heart failure are most likely due to severely altered
intracellular Ca handling and arrhythmogenic events in vitro and in
vivo. In rabbit cardiomyocytes isolated from healthy or failing hearts
respectively, spontaneously occurring Ca waves could be suppressed
by CaMKII inhibition. CaMKII inhibition also effectively antagonized
the arrhythmic effects of isoproterenol treatment [37]. Furthermore,
it has recently been shown that digitalis induced arrhythmias are at
least in part CaMKII mediated [38]. Treatment of rat cardiomyocytes
with ouabain increased CaMKII autophosphorylation and provoked
spontaneous electric activity and Ca waves. These arrhythmic events
could, in turn, be reduced by CaMKII inhibition.
Similar results could be obtained from human cardiac tissue. We
have recently shown that CaMKII activity is increased in human AF
compared to sinus rhythm, associatedwith increased RyR phosphoryla-
tion at the CaMKII site [25]. In line with this, we observed an increased
SR Ca leak in AF, which was due to CaMKII mediated effects as it could
be completely normalized by CaMKII inhibition. Additionally, CaMKII
inhibition could effectively normalize elevated diastolic Ca levels in
AF, which consecutively reduced the transient inward current via NCX
and suggests that the CaMKII-dependent SR Ca leak could play an
important role in the initiation and maintenance of human AF. These
data were recently conﬁrmed by a study of another group, which
also demonstrated increased CaMKII-dependent SR Ca leak in AF and
veriﬁed increased open probability of RyR2 in AF by single channel
recordings [26]. This important role of CaMKII mediated SR Ca leak is
further corroborated by the ﬁnding that mice with mutated RyR2 that
cannot be phosphorylated by CaMKII (S2814A mutation) are protected
from AF [39,40].
1.3. L-type Ca channels
L-type Ca channels (LTCC) are voltage dependent Ca channels
located in the plasma membrane that open up rapidly during systole
upon the onset of an action potential. The LTCC protein complex
includes a pore forming α-subunit (Cav1.2) and accessory β-subunits
[41]. The Ca ions entering the cell via LTCC (ICa) then bind to RyR2 inthe membrane of the SR and initiate Ca induced Ca release (CICR).
LTCCs and clusters of RyR2 are physiologically situated in close proximity
due to invaginations of the plasma-membrane (T-tubuli) forming the
dyadic cleft. These subcellular ultrastructures facilitate CICR but have
been found to be impaired in heart failure [42]. As CaMKII is thought to
be attached to the RyR2-LTCC microdomain, it is not surprising that it
functionally modulates not only RyR2 but also LTCC. It was shown that
CaMKII can phosphorylate the β2a-subunit of the LTCC at Thr498 [43]
and promotes the entry of the LTCC into a highly active gating mode
(mode 2) [13]. Thismode is characterized by frequent and long openings
of the LTCC and most likely underlies ICa facilitation, which is a positive
feedback mechanism augmenting L-type Ca currents and slowing
down ICa inactivation in response to increased intracellular Ca concentra-
tions. Models that prevent mode 2 gating also interrupted ICa facilitation
[35].
Mode 2 gating altogether leads to an increase in Ca inﬂux via the
LTCC and is known to promote early afterdepolarizations under certain
conditions [44,45]. These are membrane potential oscillations taking
place during the plateau or late repolarization phase of an action poten-
tial [46]. Furthermore, an increased Ca inﬂux likewise leads to a cyto-
plasmic Ca overload and hence promotes NCX-dependent transient
inward currents and consecutively delayed afterdepolarizations. Early
as well as delayed afterdepolarizations, as discussed earlier, consti-
tute potent triggers for arrhythmias. It was shown in a rabbit model
of long-QT-syndrome that a drug-induced switch of LTCC into
mode 2 gating can effectively induce polymorphic ventricular
tachycardia [47]. It could also be shown that a sole overexpression
of WT β2a-subunits in paced adult rabbit cardiomyocytes causes
cellular Ca overload, membrane potential oscillations and even pre-
mature death by favoring mode 2 gating [43]. This effect could be
counteracted by CaMKII inhibition and was attenuated when mu-
tant β2a-subunits lacking the CaMKII dependent phosphorylation
site Thr498 were overexpressed. Thus, these data conﬁrm the funda-
mental role of CaMKII for LTCC mode switch and ICa facilitation. Inter-
estingly, the β2a-subunit of LTCC was found to be overexpressed in
human heart failure [48]. This, alongside with an increased CaMKII
activity, leads to elevated Cav1.2 currents and can be assumed to con-
tribute to the high arrhythmogenity.
Importantly, although the shortening of action potential duration
in AF due to reduced L-type Ca current is believed to contribute to
the perpetualization of AF and CaMKII inhibition might be expected
to further reduce this current, this appears not to be the case: studies
from our group [25] as well as from another group have shown that
CaMKII inhibition does not further decrease the L-type Ca current in
AF. So in this pathology, CaMKII inhibition could speciﬁcally target
185T.H. Fischer et al. / Journal of Molecular and Cellular Cardiology 58 (2013) 182–187one arrhythmogenic mechanism (SR Ca leak) while not further
aggravating the other (reduced L-type Ca current).1.4. Na channels
Inﬂux of Na ions via voltage-dependent Na channels during an
action potential has a depolarizing effect on the membrane potential.
Twomajor types of Na currents have been identiﬁed in cardiomyocytes
[49]. First, there is a rapid and quickly inactivating (1–10 ms) Na
current (peak Na current, mostly Nav1.5) leading to the steep upstroke
of the action potential. Second, there is a background Na conductance
that is rather small in amplitude but persists throughout the whole
action potential (late Na current, INa,late). This late Na current has been
found to be increased under various pathological conditions [50–52].
Due to its long duration, the integral of INa late may exceed that of
peak INa and contribute to cellular Na overload and prolongation of
the AP duration (APD). Accordingly, it has been shown that an increased
Na inﬂux contributes to action potential prolongation in heart failure
[51]. Increased action potential duration translates into a prolonged
QT interval and constitutes a major risk factor for sudden cardiac
death caused by ventricular tachycardia or ﬁbrillation.
It could be shown that calmodulin can bind to cardiac Na channels
slowing down their inactivation and consecutively triggering ventricular
arrhythmias [53]. This effect may be partly attributed to CaMKII activa-
tion. We could show that acute and chronic overexpression of CaMKII
in rabbit and mouse ventricular cardiomyocytes leads to a robust
increase of late Na current and intracellular Na concentration [14]
(see Fig. 3). Additionally, we demonstrated that reactive oxygen species
(ROS) can effectively enhance CaMKII autophosphorylation and oxida-
tion and consecutively increase lateNa current [54]. Thismechanismpos-
sibly partly underlies late INa activation in human heart failure as the
generation of ROS is increased due to ischemia. The effect was abolished
in CaMKII(−/−) mice [54]. Furthermore, CaMKII overexpression also
slowed fast INa inactivation, enhanced the accumulation of intermediate
INa inactivation and shifted steady-state inactivation of Na channels to a
more negative membrane potential [14]. Interestingly, these alterations
in Na gating resemble the phenotype seen in genetic disorders of cardiac
excitability, such as the long QT syndrome type 3 and Brugada syn-
drome [55,56], both ofwhich are known for the increased risk of sudden
cardiac death [57]. Accordingly, isolated papillary muscles of transgenic
mice overexpressing CaMKII exhibited premature arrhythmogenic con-
tractions, which could be effectively suppressed with the late INa inhib-
itor ranolazine [58]. In vivo, these mice showed prolonged QT intervals
and QRS durations and a raised propensity for ventricular arrhythmias
[14]. These studies hence conﬁrm the proarrhythmic potential of a
CaMKII dependent modulation of Na gating. Additionally, it was also
shown that an increased late Na current can, in turn, activate CaMKIIFig. 3. CaMKII-dependent arrhythmogenic mechanisms: late Na current: original registra-
tions illustrating increased lateNa current in cardiomyocytes overexpressing CaMKIIδc com-
pared to control (β-gal). Late Na current could be normalized in CaMKIIδc overexpressing
cells by CaMKII-inhibition with KN-93.
Modiﬁed fromWagner et al., JCI, 2006.[59]. Treatment of neonatal rat cardiomyocytes with the late INa en-
hancer sea anemone toxin II (ATX II) increased CaMKII autophosphoryl-
ation resulting in CaMKII dependent hyperphosphorylation of target
proteins like PLN and RyR2. Thus, a vicious circle could take root in
the diseased heart that maintains CaMKII activation and late INa aug-
mentation and thus aggravates the propensity for arrhythmias.
1.5. K channels
In contrast to Na and Ca ions, the highest potassium concentration
is found inside cardiomyocytes under steady-state conditions leading
to K outward currents upon opening of K-channels. The concentration
gradient is maintained via the Na/K pump in the plasma membrane.
During an action potential, voltage-gated K outward currents (IK)
are the major driving force for membrane repolarization. IK thus
modulates action potential duration. A reduction of IK is a frequent
ﬁnding in cardiac disease leading to a prolongation of the QT interval.
Furthermore, the long QT syndrome type 1 (LQT1) can be attributed
to mutations in cardiac K channels, which result in a decreased
repolarizing K current and exhibit a high risk for live threatening
arrhythmic events [60]. IK consists of the short transient outward K
current (Ito) and the inwardly rectifyingK current (IK1). Ito, in turn, com-
prises a fast and a slow component, Ito,fast (Kv4.2/Kv4.3) and Ito,slow
(Kv1.4). We demonstrated that acute and chronic overexpression of
CaMKII increases Ito,slow current and the expression of Kv1.4 protein
[61]. The threonine residue at position 602 of the Kv1.4 protein was
identiﬁed as a potential target for CaMKII dependent phosphorylation
[62]. Ito,fast currents however were found to be reduced upon chronic
overexpression of CaMKII in mice, with the corresponding channel-
protein (Kv4.2) being downregulated [61]. As these alterations of K
currents could not be reversed by drug-based CaMKII inhibition, one
has to assume a CaMKII-dependent regulation of channel expression
or trafﬁcking rather than direct Ito modiﬁcation at the channel protein.
In contrast to that, the recovery from inactivation was accelerated
by an overexpression of CaMKII and could acutely be reversed by
CaMKII inhibition. Furthermore, chronic overexpression of CaMKII
leads to downregulation of the inward rectifying current IK1, whereas
acute overexpression of CaMKII increased IK1. Accordingly, chronic
overexpression of CaMKII in mice prolonged APD via reduction of Ito,fast
and IK1 as well as an induction of Na currents (see above) whereas an
acute overexpression of CaMKII in rabbit cardiomyocytes shortened
APD (consistent with enhanced IK1 and Ito,slow and faster Ito recovery)
[61]. Furthermore, it was shown that the chronic inhibition of CaMKII
by transgenic expression of an inhibitory peptide in mice leads to
an upregulation of Ito,fast and IK1 and consecutively shortens the
QT-interval [63]. This study therefore conﬁrms the hypothesis that the
reduction of K-currentsmight be anothermechanismof a CaMKII depen-
dent QT-prolongation in the context of chronically elevated CaMKII
activity, as it is present in various human cardiac diseases [25,29].
Indeed, it could be shown in human cardiac tissue that the expression
of Kv4.2/Kv4.3 is reduced in heart failure [64]. The effects of CaMKII
activity on K-gating in cardiomyocytes, however, seem to be crucially
dependent on the timeframe (acute vs. chronic) and obviously involve
direct modulations of the gating properties of channel proteins as well
as effects on channel protein expression.
2. Conclusion
The current literature thus provides compelling evidence for the
arrhythmogenic potency of CaMKII overactivity in cardiac disease.
All major classes of proteins involved in the formation of an action
potential (voltage gated Na and K channels, L-type Ca channels) as
well as key SR Ca handling proteins (RyR2, PLN) have been shown
to be modulated by CaMKII — with potentially proarrhythmic effects.
This has also been veriﬁed by computational models [65]. Taken to-
gether, these data thus underline the therapeutic potential of CaMKII
186 T.H. Fischer et al. / Journal of Molecular and Cellular Cardiology 58 (2013) 182–187inhibition in human cardiac pathologies such as heart failure. The possi-
bility to elegantly combine inotropic and antiarrhythmic therapies by
targeting a cellular mechanism that is responsible for both would
thereby be a unique feature of this approach. First studies have already
demonstrated antiarrhythmic effects of CaMKII inhibition. Further
research will allow us to more clearly deﬁne conditions where CaMKII
inhibition would be most potent for antiarrhythmic application. The
organ speciﬁc application of CaMKII inhibitors, however, might be a
major hurdle still to be overcome as CaMKII has been shown to be of
major importance for memory consolidation and neuronal excitability.
Consequently, the safety of CaMKII inhibition as a therapeutic strategy
has to be further validated before being considered for human use.
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